Everybody has heard the axiom “time is money,†which highlights the belief that time is a valuable resource; therefore, it is better to do things as quickly as possible in order to make more money. This concept perfectly describes the current atmosphere within the biopharmaceutical industry, where drug manufacturers are struggling to overcome speed-to-market challenges in order to reap the financial benefits of an optimized patent window. In order to bring their products to market, most biopharmaceutical-manufacturing systems employ a…
Tuesday, October 22, 2019 Daily Archives
Glenmark takes bi-specific stance in Ichnos spin-out
Glenmark spin-out Ichnos Sciences wants its pipeline of biologic and small molecule drug candidates to be generating clinical data within two years. New Jersey Ichnos announced its plan this week to coincide with the official launch of the company. It said it will progress its most advanced assets – the cancer drugs GBR 1302 and GBR 1342, the autoimmune disease MAb GBR 830, and the non-opioid pain meds GRC 27864 and GRC 17536 – through trials by 2021. Biologics The…
Chinese CMC: CMAB to make bi-functional antibody for BJ
BJ Bioscience has contracted CMAB Biopharma to provide research, development and manufacturing services for a candidate therapeutic antibody called BJ-005. Under the deal, CMAB will conduct CMC development and manufacturing to support the planned submission of an IND for the candidate drug in China and the US. No further details about BJ-005 were provided. According to BJ Biosciences’ website the drug is a bi-functional antibody intended for the treatment of “cancer.†On the firm’s pipeline page the timing for IND…